- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01459107
Human Upper Extremity Allotransplantation
Background: Millions of people each year sustain injuries, have tumors surgically removed, or are born with defects that require complex reconstructive surgeries to repair. In the case of hand, forearm, or arm amputation, prostheses only provide less than optimal motor function and no sensory feedback. However, hand and arm transplantation is a means to restore the appearance, anatomy, and function of a native hand. Although over 70 hand transplants have been performed to date and good functional results have been achieved, widespread clinical use has been limited due to adverse effects of life-long and high-dose immunosuppression needed to prevent graft rejection. Risks include infection, cancer, and metabolic problems, all of which can greatly affect recipients' quality of life, make the procedure riskier, and jeopardize the potential benefits of hand transplantation.
Study Design: This non-randomized, Phase II clinical trial will document the use of a new immunomodulatory protocol (aka - Pittsburgh Protocol, Starzl Protocol) for establishing hand transplantation as a safe and effective reconstructive treatment for upper extremity amputations by minimizing maintenance immunosuppression therapy in unilateral and bilateral hand/forearm transplant patients. This protocol combines lymphocyte depletion with donor bone marrow cell infusion and has enabled graft survival using low doses of a single immunosuppressive drug followed by weaning of treatment. Initially designed for living-related solid organ donation, this regimen has been adapted for use with grafts donated by deceased donors. The investigators propose to perform 30 human hand transplants employing this novel protocol.
Specific Aims: 1) To establish hand transplantation as a safe and effective reconstructive strategy for the treatment of upper extremity amputations; 2) To reduce the risk of rejection and enable allograft survival while minimizing the requirement for long-term high dose multi-drug immunosuppression.
Significance of Research: Hand transplantation could help upper extremity amputees recover functionality, self-esteem, and the capability to reintegrate into family and social life as "whole" individuals. The protocol offers the potential for minimizing the morbidity of maintenance immunosuppression, thereby beneficially shifting the risk/benefit ratio of this life-enhancing procedure and enabling widespread clinical application of hand transplantation.
Study Overview
Status
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Recruiting
- Johns Hopkins University School of Medicine
-
Principal Investigator:
- Jaimie Shores, MD
-
Contact:
- Carisa M Cooney, MPH, CCRP
- Phone Number: 443-287-4629
- Email: ccooney3@jhmi.edu
-
Sub-Investigator:
- Damon S Cooney, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Recipient Inclusion Criteria:
- Recent (≥6 months) or remote (i.e., several decades) unilateral or bilateral upper limb loss (below the shoulder) desiring limb transplantation.
- Below-shoulder amputation.
- Functionless or minimally functional hand desiring removal of functionless / minimally functional hand followed by transplantation.
- Male or female and of any race, color or ethnicity.
- Aged 18-69 years.
- Completes the protocol informed consent form.
- No co-existing medical condition which, in the opinion of the study team, could affect the immunomodulatory protocol, surgical procedure, or functional results (see Donor and Recipient Exclusion Criteria below. If the condition is amenable to treatment, the study team must agree that said condition should not significantly enhance the surgical risks of upper extremity transplantation.)
- No co-existing psycho-social problems (i.e., alcoholism, drug abuse).
- Negative for malignancy for past 5 years.
- Negative for HIV at transplant.
- Negative crossmatch with donor.
- If female of child-bearing potential, negative serum pregnancy test.
- If female of child-bearing potential, consent to use reliable contraception for at least one year following transplantation.
- Consents to bone marrow infusion as part of the treatment regime.
- USA citizen or equivalent, or foreigner with documentation of ability to pay for transplant and required follow-up care.
- Patient agrees to comply with the protocol and states a dedication to the immunomodulatory treatment regime.
Donor Inclusion Criteria:
Donors will be selected by the upper extremity transplant team in conjunction with the organ procurement organization (OPO) according to the following criteria:
- Brain dead meeting the criteria for Determination of Death.
- Family consent for limb donation.
- Stable donor (i.e., does not require excessive vasopressors to maintain blood pressure).
- Aged 16 - 65 years.
- Limb matched for size with recipient.
- Same blood type as recipient.
- Negative lymphocytotoxic crossmatch.
- Accurately matched for gender, skin tone, and race (relative requirements depending on recipient consent).
Exclusion Criteria:
• Positive for any of the following conditions:
- Untreated sepsis.
- HIV (active or seropositive).
- Active tuberculosis.
- Hepatitis B or C.
- Viral encephalitis.
- Toxoplasmosis.
- Malignancy (within past 5 years).
- Current/recent (within 3 months of donation/screening consent) IV drug abuse.
- Paralysis of ischemic or traumatic origin.
- Inherited peripheral neuropathy.
- Infectious, post infectious, or inflammatory (axonal or demyelinating) neuropathy.
- Toxic neuropathy (i.e. heavy metal poisoning, drug toxicity, industrial agent exposure).
- Mixed connective tissue disease.
- Severe deforming rheumatoid or osteoarthritis in the limb.
Donor Only:
• Tattoos:
- Non-professional tattoo within last 6 months, or
- Personally identifiable tattoo (i.e., donor name) on potential transplant.
Recipient Only:
- Type I (insulin-dependent) diabetes mellitus
- Conditions that, in the opinion of the study team, may impact the immunomodulatory protocol potentially exposing the recipient to an unacceptable risk under immunosuppressive treatment.
- Sensitized recipients with high levels (50%) of panel-reactive human leukocyte antigen (HLA) antibodies.
- Conditions that may impact the success of the surgical procedure or increase the risk of postoperative complications including inherited coagulopathies like Hemophilia, Von-Willebrand's disease, Protein C and S deficiency, Thrombocythemias, Thalassemias, Sickle Cell disease, etc.
- Mixed connective tissue diseases and collagen diseases can result in poor wound healing after surgery.
- Conditions that may impact functional outcomes including Lipopolysaccharidosis and amyloidosis (may impact nerve regeneration) or rare disorders of bone healing like osteopetrosis.
- Patients considered unsuitable per the consulted Psychiatrists appraisal.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (Transplantation)
Hand/arm transplantation in combination with a novel donor bone marrow cell-based therapy followed by single-drug immunosuppression with potential weaning.
|
Deceased donor hand is surgically attached to recipient arm's stump.
This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human upper extremities under low-dose maintenance immunosuppression.
Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy.
Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones.
Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Graft Survival
Time Frame: Transplantation through end of study period (up to 5 years)
|
Post-operative graft survival will be documented monthly Months 1-12 and quarterly (every 3 months) Years 2-5.
|
Transplantation through end of study period (up to 5 years)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Documentation of immunosuppression required by transplanted participants to maintain graft.
Time Frame: Transplantation to end of study period (up to 5 years)
|
Post-operative serum trough levels will be documented daily Days 1-28, semiweekly Weeks 5-12, weekly Weeks 13-25, biweekly Weeks 26-38, monthly Months 10-12, and quarterly (every 3 months) Years 2-5.
|
Transplantation to end of study period (up to 5 years)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jaimie Shores, MD, Johns Hopkins University
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NA_00046418
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Wounds and Injuries
-
3MWithdrawn
-
Centre Hospitalier Universitaire de NīmesCompletedWounds and Injuries, Hands | Wounds and Injuries, Wrists | Wounds and Injuries, Feet | Wounds and Injuries, AnklesFrance
-
Samsung Medical CenterCompletedNeedle Stick InjuriesKorea, Republic of
-
Assaf-Harofeh Medical CenterUnknownInjuries and Wounds
-
Karolinska InstitutetCompletedWounds and Injuries | Blast Injuries | War-Related Injuries | Gunshot WoundSweden
-
Hospital Universiti Sains MalaysiaActive, not recruiting
-
Medical University of South CarolinaCompletedNeedlestick InjuriesUnited States
-
Karolinska InstitutetMedecins Sans Frontieres, NetherlandsCompletedWounds and Injuries | Leg Injuries | Soft Tissue Injuries | Wound Infection | Arm Injuries | Wounds, Penetrating | Wounds, Gunshot | War-Related InjuriesJordan
-
HTL-Strefa S.A.CompletedAccident InjuryUnited States
Clinical Trials on Deceased donor hand transplantation
-
Samsung Medical CenterCompletedDeceased Donor Kidney Transplantation | Living Donor Kidney TransplantationKorea, Republic of
-
Rennes University HospitalRecruitingUterine Factor InfertilityFrance
-
University Health Network, TorontoRecruitingIntrahepatic CholangiocarcinomaCanada
-
University of GiessenNovartis; Astellas Pharma US, Inc.; German Cancer Research Center; Heidelberg UniversityCompletedKidney Transplantation | Immunology | Virus | Living Donors | Rituximab (RTx)Germany
-
University of Maryland, BaltimoreLiving Legacy FoundationCompleted
-
Johns Hopkins UniversityUniversity of Colorado, Denver; National Institute of Allergy and Infectious... and other collaboratorsRecruitingHIV InfectionUnited States
-
Johns Hopkins UniversityRecruitingFacial Injuries | Facial Deformity | Craniofacial Defects | Craniofacial Injuries | Traumatic Wounds and Injuries | Facial TransplantationUnited States
-
Stanford UniversityEnrolling by invitationImmune ToleranceUnited States
-
Institute for Clinical and Experimental MedicineSahlgrenska University Hospital, Sweden; University Hospital, MotolRecruitingInfertility, Female | Mayer Rokitansky Kuster Hauser Syndrome | Absolute Uterine Factor Infertility | Mullerian Aplasia | Uterus; Absence, Congenital | Uterus Absence, AcquiredCzechia
-
Cedars-Sinai Medical CenterRecruitingOrgan TransplantUnited States